Total Assets$Novo Nordisk AS(NVO.US)Bad news is over, waiting for a strong comeback
Goldman Sachs: Novo Nordisk's pricing pressure is overvalued by the market, and oral Wegovy will be key to restoring confidence
Goldman Sachs stated that the current stock price has fully absorbed the most pessimistic expectations for the fiscal year 2026. The market has underestimated the sales potential of Medicare's release and the revenue prospects of the oral version of Wegovy. The launch of oral Wegovy has performed strongly, with 50,000 prescriptions written, 90% of which are out-of-pocket demand, indicating a rigid market potential that will be key to restoring investor confidence
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
